Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 11Unknown 3Active not recruiting 3Recruiting 2Terminated 1

Sponsor Class

OTHER 6NIH 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2

Conditions

Neoplasms 30Prostatic Neoplasms 22Neoplasm Metastasis 20Breast Neoplasms 17Lung Neoplasms 16Colorectal Neoplasms 15Leukemia, Myeloid, Acute 14Pancreatic Neoplasms 13Ovarian Neoplasms 12Urinary Bladder Neoplasms 11Lymphoma 11Hematologic Neoplasms 11Carcinoma, Non-Small-Cell Lung 10Stomach Neoplasms 9Myelodysplastic Syndromes 9Squamous Cell Carcinoma of Head and Neck 8Sarcoma, Kaposi 8Pheochromocytoma 8Multiple Myeloma 8Melanoma 8Lymphoma, Non-Hodgkin 8Leukemia, Lymphocytic, Chronic, B-Cell 8Endometrial Neoplasms 8Carcinoma, Renal Cell 8Burkitt Lymphoma 8Neuroendocrine Tumors 7Mouth Neoplasms 7Kidney Neoplasms 7Glioma 7Thyroid Neoplasms 6

Interventions

Specimen Handling 2Doxorubicin 2peposertib 1pembrolizumab 1liposomal doxorubicin 1X-Rays 1Magnetic Resonance Spectroscopy 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × NIH × Histiocytoma, Malignant Fibrous × Clear all
NCT06422806 2026-05-29

Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

National Cancer Institute (NCI)

Phase 3 Recruiting
365 enrolled
Sarcoma

Liposarcoma, Histiocytoma, Malignant Fibrous

NCT05711615 2026-05-15

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

National Cancer Institute (NCI)

Phase 1 Recruiting
30 enrolled
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡